FRAMINGHAM, Mass., Nov. 7, 2014 /PRNewswire/ -- HeartWare
International, Inc. (NASDAQ:HTWR), a leading innovator of less
invasive, miniaturized circulatory support technologies that are
revolutionizing the treatment of advanced heart failure, today
announced that CEO Doug Godshall is
scheduled to present at the Credit Suisse 2014
Healthcare Conference at 2:00 p.m.
MST (4:00 pm EST) on
Wednesday, November 12, 2014.
The conference is being held November
10-13 at the Arizona Biltmore in Phoenix.
A live webcast of the Company's presentation at the conference
will be available via a link provided at www.heartware.com. A
replay of the webcast will be available for 90 days at the site
after the presentation.
About HeartWare International
HeartWare International develops and manufactures miniaturized
implantable heart pumps, or ventricular assist devices, to treat
patients suffering from advanced heart failure. The
HeartWare® Ventricular Assist System features the
HVAD® pump, a small full-support circulatory assist
device designed to be implanted next to the heart, avoiding the
abdominal surgery generally required to implant competing devices.
The HeartWare System is approved in the
United States for the intended use as a bridge to cardiac
transplantation in patients who are at risk of death from
refractory end-stage left ventricular heart failure, has received
CE Marking in the European Union and has been used to treat
patients in 40 countries. The device is also currently the subject
of a U.S. clinical trial for destination therapy. For additional
information, please visit the Company's website at
www.heartware.com.
HeartWare International, Inc. is a member of the Russell
2000® and its securities are publicly traded on The
NASDAQ Stock Market.
HEARTWARE, HVAD, MVAD, PAL, SYNERGY, CIRCULITE and HeartWare
logos are registered trademarks of HeartWare, Inc.
For further information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartware.com
Phone: +1 508 739 0864
SOURCE HeartWare International, Inc.